Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
APRE Stock Chart & Stats
$0.94
-$0.03(-0.72%)
At close: 4:00 PM EST
$0.94
-$0.03(-0.72%)
Day’s Range― - ―
52-Week Range$0.84 - $4.65
Previous CloseN/A
Volume2.88K
Average Volume (3M)55.77K
Market Cap
$6.57M
Enterprise Value-$5.52M
Total Cash (Recent Filing)$13.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 26, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding6,993,838
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.94
Price to Sales (P/S)12.06
P/FCF Ratio-1.34
Enterprise Value/Market Cap-0.84
Enterprise Value/Revenue-11.31
Enterprise Value/Gross Profit0.88
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$5.00Price Target Upside431.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsEarly but promising clinical efficacy from the APR-1051 dose-escalation study sets the stage for near-term catalysts.
Financial StabilityRecent financing extends cash runway into 1Q27, allowing continued advancement of lead program APR-1051.
Strategic FocusStrategic focus on HPV+ cancers within the APR-1051 program creates potential for a faster path to registration with a specific biomarker-defined population.
Bears Say
Financial ConcernsATRN-119 monotherapy study paused to conserve cash; combination strategies will be pursued as financing permits.
Industry ChallengesIssues in the synthetic lethality space, particularly for companies like Repare and Zentalis, cast a shadow over Aprea.
Market PerformanceAprea's share price has pulled back to near an all-time low, driven by factors unrelated to the synthetic lethality pipeline.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.84 and its highest was $4.65 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $6.57M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 73 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.13.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.4.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 6,993,838 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$5.00
▲(431.91% Upside)
Technical Analysis
Ownership Overview
11.34% Insiders
3.14% Mutual Funds
20.05% Other Institutional Investors
65.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---